Sheridan Group Hospital is the First Healthcare Establishment in Michigan With Nociscan
Settlement Expands Nociscan Entry to John Keller, MD, a Main Neurosurgeon and Aclarion Medical Advisor, and the Sufferers he Serves in Central Michigan
BROOMFIELD, CO, Aug. 14, 2024 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the placement of continual low again ache, introduced at present it has established a business settlement with Sheridan Group Hospital in Sheridan, Michigan. The settlement brings Nociscan to central Michigan and main neurosurgeon, John Keller, MD.
“As I work by the right way to finest deal with my sufferers, I’m excited to work with Sheridan Hospital and Nociscan to proceed to develop secure, noninvasive, and cost-effective instruments to assist in the exact identification of disc ache,” stated John Keller, MD, Neurosurgeon. “Constructing upon the proof that’s already mounting in favor of utilizing MR spectroscopy and Nociscan is essential work that I’m enthusiastic to undertake.”
Persistent low again ache (cLBP) is a world healthcare downside with roughly 266 million individuals worldwide affected by degenerative spine illness and low again ache. Aclarion’s Nociscan resolution is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. When used with different diagnostic instruments, Nociscan offers important insights into the placement of a affected person’s low again ache.
“At Sheridan Group Hospital, we’re dedicated to bringing dedication and experience to supply individual-based skilled well being take care of the households in our neighborhood – and past,” says Lili Petricevic, CEO of Sheridan Group Hospital. “We’re thrilled to have interaction with Aclarion and produce their modern resolution, Nociscan, to our neighborhood. Low again ache impacts our neighborhood and Nociscan will probably be a precious determination help software when selecting therapy choices.”
Aclarion has not too long ago introduced insurance coverage protection within the UK from main insurers. Introducing Nociscan in markets like Sheridan continues the development of offering entry as a step on the trail to payer protection within the US.
For extra details about Sheridan Hospital, please go to: https://www.sheridanhospital.com
For extra details about Dr. Keller, please go to: https://greatlakesneuro.com
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize medical therapies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Via a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) information from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers important insights into the placement of a affected person’s low again ache, giving physicians readability to optimize therapy methods.
For extra info, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch comprises forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic details, resembling “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to a variety of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Change Fee. Readers are inspired to assessment the part titled “Danger Elements” within the Firm’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2023, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Change Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
Discussion about this post